 |
Yondelis to be filed for ovarian cancer after Phase III success
Wednesday 13 August 2008
Malini Guha - Science Editor
PharmaMar's anticancer Yondelis (trabectedin) has succeeded in extending progression-free survival (PFS) in its pivotal Phase III trial in relapsed ovarian cancer, and the Spanish company and its US partner Ortho Biotech (Johnson & Johnson) will seek both EU and US approval before the end of the year for this important indication.
PFS was the primary endpoint of the 650-patient ET743-OVA-301 trial. Secondary endpoints included overall survival, response rate and safety. PharmaMar (a subsidiary of Zeltia) was unable to comment on any of these...
Login to view the full article
- Not a subscriber? Request a FREE trial
- Subscribe to Scrip
- Email to a friend
Comments
No Comments Yet
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
